03/22/23 7:00 AMNasdaq : TNXP conferencesTonix Pharmaceuticals to Present at the 2023 Virtual March Investor SummitTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday,RHEA-AIneutral
03/16/23 4:05 PMNasdaq : TNXP partnershipTonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership SummitTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, will deliver aRHEA-AIneutral
03/16/23 7:00 AMNasdaq : TNXP clinical trialTonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)Results from Planned Interim Analysis Expected Fourth Quarter 2023 Approximately 21 Million Adults in U.S. Suffer From a Major Depressive Episode Each Year TNX-601 ER is a Once-Daily Tablet that is Bioequivalent to Three-Times-Daily Tianeptine Sodium Immediate Release (IR) that has been availableRHEA-AIneutral
03/13/23 7:00 AMNasdaq : TNXP earningsTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsInterim Analysis of Registration-Enabling Phase 3 Fibromyalgia Trial of TNX-102 SL Expected Second Quarter 2023; Topline Data Expected Fourth Quarter 2023 Potentially Pivotal Phase 2 Trials of TNX-1900 in Chronic Migraine and TNX-601 ER in Depression Scheduled for Interim Analyses in Fourth QuarterRHEA-AIneutral
03/07/23 7:00 AMNasdaq : TNXP clinical trialTonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, “Cancer Immunotherapy: Mechanisms of Response Versus Resistance”Murine TNX-1700 (mTNX-1700) Enhances Anti-Tumor Activity of PD-1 Blockade in Mouse Models of Colorectal Cancer TNX-1700 is in Development as Monotherapy and in Combination with Anti-PD-1 Checkpoint Inhibitor Therapy for Colorectal and Gastric Cancers In Animal Models of Colorectal Cancer, mTNX-1700RHEA-AIneutral
02/23/23 4:15 PMNasdaq : TNXP managementTonix Pharmaceuticals Announces New Board Member, R. Newcomb StillwellTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of R. Newcomb Stillwell to its Board of Directors, to be effective as of March 15, 2023. “We areRHEA-AIneutral
02/22/23 7:00 AMNasdaq : TNXP covid-19Tonix Pharmaceuticals Describes Emerging Research on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients During Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”Symptoms of Long COVID, Like Multi-Site Pain, Fatigue and Insomnia, are the Hallmarks of Chronic Pain Syndromes Like Fibromyalgia and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Event Co-Hosted by the Biotechnology Innovation Organization (BIO) and Solve M.E., an Advocacy Group forRHEA-AIneutral
02/16/23 7:00 AMNasdaq : TNXP conferencescovid-19Tonix Pharmaceuticals to Participate in Event Titled, “Long COVID: What Will it Take to Accelerate Therapeutic Progress?”Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), aRHEA-AIneutral
02/13/23 7:00 AMNasdaq : TNXP Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal AntibodiesRHEA-AIneutral
02/09/23 7:00 AMNasdaq : TNXP Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company’s Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)TonixRHEA-AIneutral